Sporanox + Lozanoc
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia
Trial Timeline
Nov 1, 2015 → Dec 1, 2016
NCT ID
NCT02621905About Sporanox + Lozanoc
Sporanox + Lozanoc is a approved stage product being developed by Mayne Pharma Group for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02621905. Target conditions include Neutropenia.
What happened to similar drugs?
7 of 17 similar drugs in Neutropenia were approved
Approved (7) Terminated (5) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02621905 | Approved | Completed |
Competing Products
20 competing products in Neutropenia